Discovery of a potent and orally available acyl-CoA: Cholesterol acyltransferase inhibitor as an anti-atherosclerotic agent: (4-Phenylcoumarin) acetanilide derivatives

Chemical and Pharmaceutical Bulletin

Volumn 59, Issue 10, 2011, Pages 1268-1273

  Ogino, Masaki ^a   Fukui, Seiji ^a   Nakada, Yoshihisa ^a   Tokunoh, Ryosuke ^a   Itokawa, Shigekazu ^a   Kakoi, Yuichi ^a   Nishimura, Satoshi ^a   Sanada, Tsukasa ^a   Fuse, Hiromitsu ^a   Kubo, Kazuki ^a   Wada, Takeo ^a   Marui, Shogo ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

(4 phenylcoumarin)acetanilide; Acyl CoA: cholesterol acyltransferase inhibitor; Atherosclerosis; Cholesterol

Indexed keywords

2 (6 CHLORO 2 OXO 4 PHENYL 2H CHROMEN 3 YL) N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 (6 CHLORO 7 METHYL 2 OXO 4 PHENYL 2H CHROMEN 3 YL) N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 (7 CHLORO 6 FLUORO 2 OXO 4 PHENYL 2H CHROMEN 3 YL) N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 (7 CHLORO 6 METHOXY 2 OXO 4 PHENYL 2H CHROMEN 3 YL) N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 (7 CHLORO 6 METHYL 2 OXO 4 PHENYL 2H CHROMEN 3 YL) N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 [7 CHLORO 4 (3 CHLORO 4 FLUOROPHENYL) 6 METHYL 2 OXO 2H CHROMEN 3 YL] N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 [7 CHLORO 4 (3 CHLOROPHENYL) 6 METHYL 2 OXO 2H CHROMEN 3 YL] N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 [7 CHLORO 4 (3,4 DIMETHYLPHENYL) 6 METHYL 2 OXO 2H CHROMEN 3 YL] N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 [7 CHLORO 4 (4 CHLOROPHENYL) 6 METHYL 2 OXO 2H CHROMEN 3 YL] N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 [7 CHLORO 4 (4 FLUOROPHENYL) 6 METHYL 2 OXO 2H CHROMEN 3 YL] N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 [7 CHLORO 6 METHYL 2 OXO 4 [3 (TRIFLUOROMETHOXY)PHENYL] 2H CHROMEN 3 YL] N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 [7 CHLORO 6 METHYL 4 (3 METHYLPHENYL) 2 OXO 2H CHROMEN 3 YL] N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; ACETANILIDE DERIVATIVE; APOLIPOPROTEIN E; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; COUMARIN DERIVATIVE; N (2 ETHYLPHENYL) 2 (2 OXO 4 PHENYL 2,6,7,8 TETRAHYDROCYCLOPENTA[G]CHROMEN 3 YL)ACETAMIDE; N (2 METHOXYPHENYL) 2 (2 OXO 4 PHENYL 2,6,7,8 TETRAHYDROCYCLOPENTA[G]CHROMEN 3 YL)ACETAMIDE; N (2,6 DIMETHOXYPHENYL) 2 (2 OXO 4 PHENYL 2,6,7,8 TETRAHYDROCYCLOPENTA[G]CHROMEN 3 YL)ACETAMIDE; N [2 FLUORO 6 (TRIFLUOROMETHYL)PHENYL] 2 (2 OXO 4 PHENYL 2,6,7,8 TETRAHYDROCYCLOPENTA[G]CHROMEN 3 YL)ACETAMIDE; N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL] 2 (2 OXO 4 PHENYL 2,6,7,8 TETRAHYDROCYCLOPENTA[G]CHROMEN 3 YL)ACETAMIDE; N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL] 2 (2 OXO 4 PHENYL 6,7,8,9 TETRAHYDRO 2H BENZO[G]CHROMEN 3 YL)ACETAMIDE; N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL] 2 (6,7 DICHLORO 2 OXO 4 PHENYL 2H CHROMEN 3 YL)ACETAMIDE; N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL] 2 (6,7 DIFLUORO 2 OXO 4 PHENYL 2H CHROMEN 3 YL)ACETAMIDE; N [4 CHLORO 2 (TRIFLUOROMETHYL)PHENYL] 2 (6,7 DIMETHYL 2 OXO 4 PHENYL 2H CHROMEN 3 YL)ACETAMIDE; N [4 FLUORO 2 (TRIFLUOROMETHYL)PHENYL] 2 (2 OXO 4 PHENYL 2,6,7,8 TETRAHYDROCYCLOPENTA[G]CHROMEN 3 YL)ACETAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ACETAMIDES; ACETANILIDES; ACYL COENZYME A; ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; ATHEROSCLEROSIS; BENZOPYRANS; CHOLESTEROL; COUMARINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053425950     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.59.1268     Document Type: Article

References (22)

1. Streja L., Packard C. J., Shepherd J., Cobbe S., Ford I., Am. J. Cardiol., 90, 731-736 (2002).
2. Braunwald E., N. Engl. J. Med., 337, 657-662 (1997).
3. Libby P., J. Intern. Med., 263, 517-527 (2008).
4. Buhman K. F., Accad M., Farese R. V., Biochim. Biophys. Acta, 1529, 142-154 (2000).
5. Chang T. Y., Chang C. C., Lin S., Yu C., Li B. L., Miyazaki A., Curr. Opin. Lipidol., 12, 289-296 (2001).
6. Chang T. Y., Li B. L., Chang C. C., Urano Y., Am. J. Physiol. Endocrinol. Metab., 297, E1-E9 (2009).
7. Oelkers P., Behari A., Cromley D., Billheimer J. T., Sturley S. L., J. Biol. Chem., 273, 26765-26771 (1998).
8. Miyazaki A., Kanome T., Watanabe T., Curr. Drug Targets Cardiovasc. Haematol. Disord., 5, 463-469 (2005).
9. Bocan T. M., Krause B. R., Rosebury W. S., Mueller S. B., Lu X., Dagle C., Major T., Lathia C., Lee H., Arterioscler. Thromb. Vasc. Biol., 20, 70-79 (2000).
10. Delsing D. J., Offerman E. H., van Duyvenvoorde W., van Der Boom H., De Wit E. C., Gijbels M. J., van Der Laarse A., Jukema J. W., Havekes L. M., Princen H. M., Circulation, 103, 1778-1786 (2001).
11. Terasaka N., Miyazaki A., Kasanuki N., Ito K., Ubukata N., Koieyama T., Kitayama K., Tanimoto T., Maeda N., Inaba T., Atherosclerosis, 190, 239-247 (2007).
12. Yoshinaka Y., Shibata H., Kobayashi H., Kuriyama H., Shibuya K., Tanabe S., Watanabe T., Miyazaki A., Atherosclerosis, 213, 85-91 (2010).
13. Ikenoya M., Yoshinaka Y., Kobayashi H., Kawamine K., Shibuya K., Sato F., Sawanobori K., Watanabe T., Miyazaki A., Atherosclerosis, 191, 290-297 (2007).
14. Tardif J. C., Gregoire J., L'Allier P. L., Anderson T. J., Bertrand O., Reeves F., Title L. M., Alfonso F., Schampaert E., Hassan A., McLain R., Pressler M. L., Ibrahim R., Lesperance J., Blue J., Heinonen T., Rodes-Cabau J., A-PLUS Investigators, Circulation, 110, 3372-3377 (2004).
15. Nissen S. E., Tuzcu E. M., Brewer H. B., Sipahi I., Nicholls S. J., Ganz P., Schoenhagen P., Waters D. D., Pepine C. J., Crowe T. D., Davidson M. H., Deanfield J. E., Wisniewski L. M., Hanyok J. J., Kassalow L. M., N. Engl. J. Med., 354, 1253-1263 (2006).
16. Meuwese M. C., De Groot E., Duivenvoorden R., Trip M. D., Ose L., Maritz F. J., Basart D. C. G., Kastelein J. J. P., Habib R., Davidson M. H., Zwinderman A. H., Schwocho L. R., Stein E. A., JAMA, 301, 1131-1139 (2009).
17. Hiatt W. R., Klepack E., Nehler M., Regensteiner J. G., Blue J., Imus J., Criqui M. H., Vasc. Med., 9, 271-277 (2004).
18. In house data.
19. Terashita Z., Nakamura M., Marui S., Ogino M., European Patent 1471064A1 (2004).
20. Compound 23 was dosed orally 10 mg/kg/5 ml, suspension in 0.5% methylcellulose, in C57/BL/6 mice (n=3).
21. Koga K., Kawashima S., Murakami M., Eur. J. Pharm. Biopharm., 54, 311-318 (2002).
22. 50 value of ACAT inhibitory activity in mouse peritoneal macrophage of compound 23 was determined to be 20 nM in the same manner as human.